StockData

PTC Therapeutics vs Ultragenyx Pharmaceutical

PTCT and RARE side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How PTCT and RARE compare

PTC Therapeutics is the larger company, worth 3.1 times as much as Ultragenyx Pharmaceutical ($5.0B against $1.6B).

Ultragenyx Pharmaceutical grew revenue faster over the last twelve months (17.5% versus −35.1% for PTC Therapeutics).

PTC Therapeutics keeps more of each dollar of sales as profit, with a net margin of −9.2% compared with −81.7% at Ultragenyx Pharmaceutical.

Ultragenyx Pharmaceutical scores higher on the StockData Score (9 against 5 for PTC Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricPTCTRARE
Size and price
Market cap$5.0B$1.6B
Share price$60.36$16.70
Change, 1 year−19.8%−49.5%
Change, 5 years58.6%−78.2%
Beta (5Y)1.092.12
Employees9911,371
StockData Score
Total score59 (better)
Valuation score11
Growth score12 (better)
Performance score2 (better)1
Health score15 (better)
Dividend score00
Valuation
P/S4.4×2.3× (better)
EV/EBITDA16.5×–
P/FCF2440×–
FCF yield0.04% (better)−29.7%
Fair value$47.05–
Margin of safety−28.3%–
Growth
Revenue growth (TTM)−35.1%17.5% (better)
Revenue growth, 5Y average35.4% (better)19.9%
Net income growth (TTM)−114%–
EPS growth (TTM)−114%–
Profitability
Operating margin12.8% (better)−73.6%
Net margin−9.2% (better)−81.7%
FCF margin0.18% (better)−68.2%
Financial health
Net debt / EBITDA−7.63–
Current ratio3.27 (better)1.73
Altman Z-score0.78 (better)−5.26
Piotroski F-score55
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions120%108%
Held by insiders3.0%4.0%
Insider net buying, 12 months−$44.2M−$3.8M (better)
Short interest, % of float9.6%25.0%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.